SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Merritt who wrote (51652)3/12/1999 4:55:00 PM
From: Knighty Tin  Read Replies (1) of 132070
 
Merritt, I think Sang's potential is tremendous. Yes, eps estimates have been cut, but this is a development stage bio stock and they have eps. I find that astounding. I knew that Novartis would sue before they were called Novartis. I think Sang wins, eventually. I know that Neoral, the Novartis drug, is way overpriced. My Mother shells out $1000 a month on it. But I think Sang missed a beat by only cutting prices 20%. 40% would have given them the entire market. 20% and they get my Mom, who is cheap like her son. <g>

I think they are making progress in their goal to become THE transplant co. And if it falls to the low teens, after popping a point after I bought calls, I will load up the truck.

I never bought Biox. I looked, twiddled my thumbs and never pulled the trigger. This is not the first time for that type of behavior on my part. <g>

MB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News